Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic β-cell function pretransplant - PubMed
3 hours ago
- #stem cell therapy
- #islet transplantation
- #type 1 diabetes
- Autologous and allogeneic stem cell-derived islet therapy was tested in three recipients with type 1 diabetes and complete loss of endogenous pancreatic β-cell function.
- The study was funded by multiple grants from Chinese national and municipal programs, including the Noncommunicable Chronic Diseases–National Science and Technology Major Project and the National Natural Science Foundation of China.
- Conflict of interest disclosures include consulting roles for Vertex, Betalin, Aspect Biosystems, and Tolerance Bio for AMJS, and EndoCell Therapeutics for XC.
- Data underlying the results are not publicly available but can be accessed through a collaborative research proposal and a signed data access agreement.